R1, R2 and R2* Relaxivity Measurements of the Contrast Agent Gadopiclenol in Human Blood; Application to Administration Strategies

Motivation: The R1, R2 and R2* relaxivity behavior of gadopiclenol in blood is unknown. Goal(s): Verify gadopiclenol blood R1 relaxivity behaves according to previously established water exchange principles and measure its blood R2 and R2* relaxivity. Approach: The R1, R2 and R2* of gadopiclenol were measured in plasma and doped human blood at 1.5 and 3T. Results: Gadopiclenol's high plasma R1 relaxivity is confirmed, and it behaves in blood as predicted. Blood R2 and R2* relaxivity are greater than those of other currently marketed gadolinium-based contrast agents (GBCAs). Impact: Different GBCAs have different relaxivity properties in blood. Knowledge of these properties allows for accurate modeling and optimization of exams such as CE-MRA, 1st pass arterial phase imaging and perfusion.